Post Market Study Using The Elite IQ Device

Hair Removal Clinical Trial

Official title:

Post Market Study Using The Elite IQ Device

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04807205
• Other study ID #: CYN20-ELITEIQ-02
• Status: Completed
• Phase: N/A
• Start date: March 26, 2021
• Est. completion date: March 2, 2022

Study information

• Verified date: June 2024
• Source: Cynosure, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, open label, single-center clinical study to collect safety and efficacy data on the Elite iQ workstation. The intended use of the Elite iQ device used in this study is for the treatment of hair removal, pseudo folliculitis barbae, and benign vascular and pigmented lesions.

Description:

Up to 20 subjects will be enrolled at up to 1 study center. Subjects will attend a screening/pretreatment visit which may be performed on the same day as the treatment visit. Subjects may receive up to 5 treatments on multiple areas of the body such as, but not limited to, the face, legs, and arms. All subjects will be required to return a follow-up visit at 30 - 90 days after the final treatment in each treatment area.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: March 2, 2022
• Est. primary completion date: March 2, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• A healthy male or female 18 years of age or older.

• Understands and accepts obligation not to receive any other procedures on the treatment area through the length of the study.

• Understands and accepts the obligation and is logistically able to be present for all visits.

• Is willing to comply with all requirements of the study and sign the informed consent document.

Exclusion Criteria:

• The subject is hypersensitive to light in the near infrared wavelength region

• The subject has sun-damaged skin (treatment contraindicated with Alex laser only)

• The subject had recent unprotected sun exposure (for Alex laser within four weeks of treatment; for Nd:YAG laser within one week of treatment), including the use of tanning beds or tanning products, such as creams, lotions and sprays

• The subject is taking medication which is known to increase sensitivity to sunlight

• The subject has seizure disorders triggered by light

• The subject is taking anticoagulants

• The subject is taking or have taken oral isotretinoin, such as Accutane®, within the last six months

• The subject is taking medication that alters the wound-healing response

• The subject has a history of healing problems or history of keloid formation

• The subject has an active localized or systemic infection, or an open wound in area being treated

• The subject has a significant systemic illness or an illness localized in area being treated

• The subject has a history of skin cancer or suspicious lesions

• The subject has an autoimmune disease

• The subject is receiving or have received gold therapy

• The subject is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within in the area to be treated 6 months to entering this study.

• The subject has any condition or is in a situation which in the investigators opinion may put the subject at significant risk, may confound study results or may interfere significantly with the subject's participation.

Related Conditions & MeSH terms

• Benign Vascular Lesion
• Folliculitis
• Hair Removal
• Pigmented Lesions
• Pseudo Folliculitis Barbae

Intervention

Device:
• RF Non-Invasive Treatment
Self-controlled single-arm group using the Elite IQ device

Locations

Country	Name	City	State
United States	Scripps Clinic Carmel Valley	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
Cynosure, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Gupta V, Sharma VK. Skin typing: Fitzpatrick grading and others. Clin Dermatol. 2019 Sep-Oct;37(5):430-436. doi: 10.1016/j.clindermatol.2019.07.010. Epub 2019 Jul 17. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blinded Evaluation of Pre-treatment Images vs. Follow up Images to Determine Which Image Was Taken Pre-treatment vs. at the Follow up.	Blind identification of pre-treatment images vs. 60 day follow up images. It is performed by independent reviewers. The outcome will be reported as a percentage of photographs identified correctly.	60 day (+/- 30 days) post last treatment
Secondary	Principle Investigator Assessment Using the Global Aesthetic Improvement Scale (PGAIS)	Principle Investigator assessment using the Global Aesthetic Improvement Scale (PGAIS) at the 60 day follow up visit. The GAIS scale ranges from 1 to 5, with 1 being "very much improved," 2 being "much improved," 3 being "improved," 4 being "no change," and 5 being "worse." This is the count of the number of subjects who the physician graded a 3 or higher.	60 day (+/- 30 days) post last treatment
Secondary	Subject Satisfaction	Subject satisfaction rates at the 60 day follow up visit. The subject satisfaction scale ranges from 1 to 6, with 1 being extremely unsatisfied, 2 being dissatisfied, 3 being slightly unsatisfied, 4 being slightly satisfied, 5 being satisfied, and 6 being extremely satisfied. This is the count of the number of subjects who graded themselves a 4 or higher.	60 day (+/- 30 days) post last treatment